Search Result

Results for "

non-enzymatic protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) GABA Receptor (1) NO Synthase (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents	Cardiovascular Disease Metabolic Disease Cancer
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

HY-141508

Flazin	Xanthine Oxidase NO Synthase	Neurological Disease Metabolic Disease Inflammation/Immunology
Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO ^-), with an IC₅₀ value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC₅₀ value of 71.99 μM for ONOO ^-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor .

HY-113033

Pentosidine	Others	Neurological Disease Metabolic Disease
Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

HY-113033A

Pentosidine TFA	Others	Neurological Disease Metabolic Disease
Pentosidine TFA is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine TFA is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

Cat. No.	Product Name	Type

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Nε-(Carboxymethyl)-L-lysine

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141508

Flazin	Simaroubaceae Source classification Plants Indole Alkaloids Brucea javanica (L.) Merr.	Xanthine Oxidase NO Synthase
Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO ^-), with an IC₅₀ value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC₅₀ value of 71.99 μM for ONOO ^-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor .

HY-113033

Pentosidine	Structural Classification Natural Products Source classification Disease markers Endogenous metabolite	Others
Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

non-enzymatic protein

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Natural
Products